Clinical trial

A Phase Ib/II Study of SHR-A1811 Injection in Breast Cancer

NCT05353361

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2022-05-23

PhasePHASE2

Study timeline

Study start (actual)2022-05-23Date precision: day

Registry last updated2023-09-15

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Breast Cancerunresolved

Interventions

SHR-A1811：PyrotinibDRUG

SHR-A1811；PertuzumabDRUG

SHR-A1811；AdebrelimabDRUG

SHR-A1811；Albumin paclitaxelDRUG

Sponsors & collaborators

Jiangsu HengRui Medicine Co., Ltd.lead sponsor

Mapped research locations

NanjingJiangsu, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05353361 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.